NASDAQ : TNYA
Tenaya Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.3984 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 89.33M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 80.97M |
| Enterprise Value | 6.83M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 17, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 224.23M |
| Shares Outstanding | 224.23M |
| Shares Change (YoY) | +73.58% |
| Shares Change (QoQ) | +0.32% |
| Owned by Insiders (%) | 0.41% |
| Owned by Institutions (%) | 21.22% |
| Float | 211.72M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 60.63 |
| Forward PS | 13.18 |
| PB Ratio | 1.17 |
| P/TBV Ratio | 1.17 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 5.10 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.52 |
| Quick Ratio | 4.12 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -121.86% |
| Return on Assets (ROA) | -47.91% |
| Return on Invested Capital (ROIC) | -55.74% |
| Return on Capital Employed (ROCE) | -110.95% |
| Weighted Average Cost of Capital (WACC) | 19.14% |
| Revenue Per Employee | $19,071 |
| Profits Per Employee | -$1.47M |
| Employee Count | 70 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.88 |
| 52-Week Price Change | -74.93% |
| 50-Day Moving Average | 0.57 |
| 200-Day Moving Average | 0.71 |
| Relative Strength Index (RSI) | 27.07 |
| Average Volume (20 Days) | 3,741,288 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 22.52M |
| Short Previous Month | 22.92M |
| Short % of Shares Out | 10.04% |
| Short % of Float | 10.64% |
| Short Ratio (days to cover) | 5.78 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.34M |
| Gross Profit | 1.34M |
| Operating Income | -82.68M |
| Pretax Income | -103.12M |
| Net Income | -103.12M |
| EBITDA | -75.52M |
| EBIT | -82.68M |
| Loss Per Share | -$0.53 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 78.09M |
| Total Debt | 3.95M |
| Net Cash | 74.14M |
| Net Cash Per Share | $0.33 |
| Equity (Book Value) | 69.41M |
| Book Value Per Share | 0.31 |
| Working Capital | 66.99M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -52.33M |
| Capital Expenditures | -263,000 |
| Depreciation & Amortization | 7.15M |
| Net Borrowing | n/a |
| Free Cash Flow | -52.59M |
| FCF Per Share | -$0.23 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -6,192.96% |
| Pretax Margin | -7,723.97% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -73.58% |
| Shareholder Yield | -73.58% |
| Earnings Yield | -147.69% |
| FCF Yield | -64.97% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $3.20 |
| Price Target Difference | 786.18% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -7.55 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |